Science and pragmatism in the treatment and prevention of neutropenic infection.
The following aspects of the management of patients with granulocytopenia and fever are reviewed in this article: adaptation of initial antibiotic regimens to the recent changes in the most common causative pathogens (namely a change from Gram-negative bacteria to Gram-positive bacteria and fungi); subsequent modifications of the empirically administered treatments; improvement of the host's defence by reducing the duration of neutropenia; and indications for out patient therapy of febrile episodes.
Klastersky
J
J
Service de Médecine Interne et Laboratoire d'Investigation Clinique H. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
D000900:Anti-Bacterial Agents; D019072:Antibiotic Prophylaxis; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005334:Fever / Q000276:immunology*; D016905:Gram-Negative Bacterial Infections / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D009181:Mycoses / Q000276:immunology / Q000517:prevention & control*; D009503:Neutropenia / Q000276:immunology*; D009894:Opportunistic Infections / Q000276:immunology / Q000517:prevention & control*
D000900:Anti-Bacterial Agents